- Home
- GOODO vs VCEL Comparison
GOODO vs VCEL Comparison
Compare GOODO & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GOODO
Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share
Current Price
Current Price
Company Overview
Basic Information| Metric | GOODO | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.4B |
| IPO Year | 2003 | 1996 |
Fundamental Metrics
Financial Performance| Metric | GOODO | VCEL |
|---|---|---|
| Price | $20.98 | $42.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.75 |
| AVG Volume (30 Days) | 5.5K | ★ 444.7K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 0.18 | N/A |
| Revenue | $161,336,000.00 | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | N/A | $18.24 |
| P/E Ratio | $116.17 | ★ N/A |
| Revenue Growth | 8.00 | ★ 16.45 |
| 52 Week Low | $19.42 | $28.95 |
| 52 Week High | $22.20 | $49.32 |
Technical Indicators
Market Signals| Indicator | GOODO | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 69.33 | 37.01 |
| Support Level | $20.25 | $32.44 |
| Resistance Level | $21.30 | $49.04 |
| Average True Range (ATR) | 0.20 | 1.57 |
| MACD | 0.02 | -0.42 |
| Stochastic Oscillator | 100.00 | 6.80 |
Price Performance
Historical ComparisonAbout GOODO Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.